FORTRESS BIOTECH INC (FBIO)
US34960Q3074 - Common Stock
Taking everything into account, FBIO scores 2 out of 10 in our fundamental rating. FBIO was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of FBIO have multiple concerns. FBIO is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
FBIO had negative earnings in the past year.
In the past year FBIO has reported a negative cash flow from operations.
In the past 5 years FBIO always reported negative net income.
FBIO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -40.99%, FBIO is doing good in the industry, outperforming 60.07% of the companies in the same industry.
The Return On Equity of FBIO (-304.59%) is worse than 74.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.99% | ||
| ROE | -304.59% | ||
| ROIC | N/A |
ROA(3y)-28.91%
ROA(5y)-23.67%
ROE(3y)-190.58%
ROE(5y)-154.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 68.45%, FBIO belongs to the best of the industry, outperforming 83.45% of the companies in the same industry.
FBIO's Gross Margin has declined in the last couple of years.
FBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.45% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.22%
GM growth 5Y-2.38%
2. Health
2.1 Basic Checks
FBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FBIO has been increased compared to 1 year ago.
FBIO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, FBIO has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -7.68, we must say that FBIO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.68, FBIO is not doing good in the industry: 72.87% of the companies in the same industry are doing better.
A Debt/Equity ratio of 2.70 is on the high side and indicates that FBIO has dependencies on debt financing.
FBIO has a Debt to Equity ratio of 2.70. This is amonst the worse of the industry: FBIO underperforms 82.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.7 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.68 |
ROIC/WACCN/A
WACC8.11%
2.3 Liquidity
FBIO has a Current Ratio of 1.38. This is a normal value and indicates that FBIO is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.38, FBIO is not doing good in the industry: 84.98% of the companies in the same industry are doing better.
FBIO has a Quick Ratio of 1.26. This is a normal value and indicates that FBIO is financially healthy and should not expect problems in meeting its short term obligations.
FBIO has a worse Quick ratio (1.26) than 84.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.26 |
3. Growth
3.1 Past
FBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.18%, which is quite impressive.
Looking at the last year, FBIO shows a quite strong growth in Revenue. The Revenue has grown by 11.57% in the last year.
The Revenue has been growing by 25.75% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)38.18%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q71.3%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y22.83%
Revenue growth 5Y25.75%
Revenue growth Q2Q21.62%
3.2 Future
The Earnings Per Share is expected to grow by 17.48% on average over the next years. This is quite good.
Based on estimates for the next years, FBIO will show a very strong growth in Revenue. The Revenue will grow by 56.57% on average per year.
EPS Next Y46.73%
EPS Next 2Y26.26%
EPS Next 3Y17.48%
EPS Next 5YN/A
Revenue Next Year4.8%
Revenue Next 2Y33.25%
Revenue Next 3Y36.1%
Revenue Next 5Y56.57%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FBIO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
FBIO's earnings are expected to grow with 17.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.26%
EPS Next 3Y17.48%
5. Dividend
5.1 Amount
No dividends for FBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FORTRESS BIOTECH INC
NASDAQ:FBIO (5/2/2024, 12:12:37 PM)
1.78
+0.04 (+2.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap34.23M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.99% | ||
| ROE | -304.59% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.45% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.7 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.26 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)38.18%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y46.73%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)11.57%
Revenue growth 3Y22.83%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y